21st International AIDS Conference (AIDS 2016)


Continued Access to Generic Drugs Needed to Enable 'Test and Treat' Strategy

August 12, 2016

On behalf of IFARA, Fred Schaich spoke at this year's International AIDS Conference with Vivian Cox, M.D., about strengthening access to generic HIV medications and the price of antiretrovirals.

India, which has "strict patent laws that allow for robust generic competition," produces 60% to 70% of the HIV drugs used in countries that permit the importing of generics, Cox said, but is under pressure to change its practices. Middle-income countries are especially hard hit by the price of antiretrovirals because they do not qualify for funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria, yet they cannot afford to buy the necessary medications on their own. Generics are not only important for providing medications to people who are already on antiretroviral therapy, but also to those who have not yet started treatment.

If South Africa, which has the largest HIV treatment program in the world, moves to a "test and treat" strategy, where everyone who tests positive for HIV receives antiretroviral therapy, it will need much larger quantities of HIV drugs. "You can't double the number of patients on treatment if you are paying a certain price that you can't afford," Cox pointed out.

The Médecins Sans Frontières Access Campaign has published a report, "Untangling the Web of Antiretroviral Price Reductions" that details the problems with exclusive patents and a lack of robust generic competition. The campaign is working with the World Health Organization and specific governments to protect access to generic medications.

Watch the video to learn more:

About the panelist:

  • Vivian Cox, M.D., Médecins Sans Frontières (Doctors Without Borders)

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2016 Remedy Health Media, LLC. All rights reserved.

Related Stories

HIV, AIDS and 90-90-90: What Is It and Why Does It Matter?
Putting HIV Science Into Practice: What Public Health Educators Must Do
HIV 'Test and Treat' Strategy Can Save Lives -- But It Needs to Be Easier for Patients to Start Treatment

This article was provided by TheBodyPRO. It is a part of the publication The 21st International AIDS Conference (AIDS 2016).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.